OncRef

Clinical Trial: NCT03721172

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Amgen
Information Provided By:Amgen
Last Update Posted:2024-05-29

Study Overview

Brief Summary

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.

Approximately 574 subjects with mild to moderate plaque psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.

Official Title

A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Mild to Moderate Plaque Psoriasis

Conditions

Psoriasis

Intervention / Treatment

  • Drug: Apremilast
  • Other: Placebo

Other Study ID Numbers

  • CC-10004-PSOR-022
  • U1111-1218-8372

Start Date (Actual)

2019-03-11

Primary Completion Date (Actual)

2020-03-06

Study Completion Date (Actual)

2020-07-24

Enrollment (Actual)

595

Study Type

Interventional

Phase

Phase 3